secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066419
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg
-------------------------------------------------------------------------

- Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.
- Cash and marketable securities $97.8M as of March 31, 2025; runway at least 12 months.
- Positive DM1 data: mean splicing correction of 29.1% 28 days after single 10 mg/kg dose of PGN-EDODM1.
- CONNECT1-EDO51 10 mg/kg dystrophin data expected Q3 2025; CONNECT2 trial voluntarily paused.
- Board added Lisa Wyman and Mitchell H. Finer, PhD in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/0000950170-25-066419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/pepg-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer